

Applicant: Soon-Shiong and Desai
Application No.: 09/628,387
Filed: August 1, 2000
Page 3

PATENT
Attorney Docket No.: ABI1150-18

IN THE CLAIMS

Please amend claims 1-3, 16, 58-60, 128, and 145 as set forth herein, and cancel claims 4-11, 30-44, 61-73, 98-101, 104-107, 110-113, 116-119, 122-125, 133-141, 149-151, 153-158, 160-162, and 164-177 without prejudice. This listing of claims will replace all prior versions, and listings, of claims in the application:

-
1. (Currently Amended) A unit dosage form comprising a sealed vial containing a sufficient quantity of cremophor-free taxane to provide for administration to a human subject a total dose of taxane in the range of about 30 mg/m² to about 1000 mg/m² over an administration period no greater than about 3 hours, wherein the cycle time between administrations of said total dose is less than about three weeks.
2. (Currently Amended) A unit dosage form according to claim 1, wherein said total dose is in the range of about 80 50 mg/m² to about 700 mg/m².
3. (Currently Amended) A unit dosage form according to claim 1, wherein said total dose is in the range of about 50 175 mg/m² to about 800 300 mg/m².
- 4-11. (Cancelled)
12. (Original) A unit dosage form according to claim 1, wherein said taxane is administered locally.
13. (Original) A unit dosage form according to claim 1, wherein said taxane is administered systemically.
14. (Original) A unit dosage form according to claim 1, wherein said taxane is in a non-aqueous formulation.

Applicant: Soon-Shiong and Desai
Application No.: 09/628,387
Filed: August 1, 2000
Page 4

PATENT
Attorney Docket No.: ABI1150-18

15. (Original) A unit dosage form according to claim 1, wherein said taxane is docetaxel.

16. (Currently Amended) A unit dosage form according to claim 1, wherein said taxane is a paclitaxel analog.

17-57. (Cancelled)

1
C
x
cont
58. (Currently Amended) A unit dosage form comprising a sealed vial containing a sufficient quantity of cremophor-free taxane to provide for administration to a human subject a total dose of taxane in the range of about 30 mg/m² to about 1000 mg/m², wherein said sealed vial comprises in the range of about 4 mg to about 822 mg of said taxane over an administration period of no greater than 3 weeks, wherein the cycle time between administrations of said total dose is less than about three weeks.

59. (Currently Amended) A unit dosage form according to claim 58, wherein said sealed vial total dose comprises in the range of about 4 30 mg to about 13 700 mg of said taxane.

60. (Currently Amended) A unit dosage form according to claim 58, wherein said sealed vial total dose comprises in the range of about 13 100 mg to about 30 400 mg of said taxane.

61-73 (Cancelled)

74. (Original) A unit dosage form according to claim 58, wherein said taxane is administered locally.

75. (Original) A unit dosage form according to claim 58, wherein said taxane is administered systemically.

76. (Original) A unit dosage form according to claim 58, wherein said taxane is in a non-aqueous formulation.

Applicant: Soon-Shiong and Desai
Application No.: 09/628,387
Filed: August 1, 2000
Page 5

PATENT
Attorney Docket No.: ABI1150-18

77. (Original) A unit dosage form according to claim 58, wherein said taxane is docetaxel.

78. (Original) A unit dosage form according to claim 58, wherein said taxane is a paclitaxel analog.

79-127. (Cancelled)

128. (Currently Amended) A cremophor-free taxane containing formulation contained within a sealed vial suitable for the delivery to a human subject of a total dose of taxane in the range of about 30 mg/m^2 to about 1000 mg/m^2 , with an administration period of no greater than about 3 hours, wherein the cycle time between administrations of said total dose is less than about three weeks.

129. (Original) A formulation according to claim 128, wherein said total dose of taxane is in the range of about 80 mg/m^2 to about 700 mg/m^2 .

130. (Previously Amended) A formulation according to claim 128, wherein said taxane is docetaxel,

131. (Original) A formulation according to claim 128, wherein said taxane is a paclitaxel analog.

132-144. (Cancelled)

145. (Currently Amended) A method for administration of cremophor-free taxane to a human subject in need thereof, said method comprising administering in the range of about 30 mg/m^2 to about 1000 mg/m^2 of said taxane to said subject in a pharmaceutically acceptable formulation contained within a sealed vial with a treatment cycle no greater than about 3 weeks, wherein said administration period is no greater than about 3 hours.

146. (Previously Amended) A method according to claim 145, wherein said taxane is docetaxel.

Applicant: Soon-Shiong and Desai
Application No.: 09/628,387
Filed: August 1, 2000
Page 6

PATENT
Attorney Docket No.: ABI1150-18

147. (Original) A method according to claim 145, wherein said taxane is a paclitaxel analog.

148-177. (Cancelled)

C
Cancelled